Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

被引：0
作者：
Sanne Bootsma
Sanne M. van Neerven
Louis Vermeulen
机构：
[1] Amsterdam University Medical Centers,Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism
[2] Oncode Institute Amsterdam,undefined
来源：
Nature Genetics | 2021年 / 53卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.
引用
收藏
页码：9 / 10
页数：1
相关论文
共 50 条
  • [41] ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
    Katarzyna Bogucka
    Federico Marini
    Sebastian Rosigkeit
    Janine Schloeder
    Helmut Jonuleit
    Kerstin David
    Margarita Schlackow
    Krishnaraj Rajalingam
    Cancer Gene Therapy, 2021, 28 : 359 - 374
  • [42] Regulation of KRas-Mediated Signaling by G-Protein Coupled Receptors in Pancreatic Cancer
    Feigin, Michael E.
    FASEB JOURNAL, 2018, 32 (01)
  • [43] Role Of Nicotine And Alpha 7 Nicotinic Acetylcholine Receptors In Kras-Mediated Lung Cancer
    Torres-Gonzalez, E.
    Ritzenthaler, J. D.
    Roman, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [44] Carnosine inhibits KRas-mediated HCT 116 proliferation by affecting ATP and ROS production
    Iannella, M. L.
    Nocella, F.
    Iovine, B.
    Schettini, V.
    Bevilacqua, M. A.
    FEBS JOURNAL, 2011, 278 : 243 - 243
  • [45] Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
    Zhang, Liang
    Yao, Yixin
    Zhang, Shaojun
    Liu, Yang
    Guo, Hui
    Ahmed, Makhdum
    Bell, Taylor
    Zhang, Hui
    Han, Guangchun
    Lorence, Elizabeth
    Badillo, Maria
    Zhou, Shouhao
    Sun, Yuting
    Di Francesco, M. Emilia
    Feng, Ningping
    Haun, Randy
    Lan, Renny
    Mackintosh, Samuel G.
    Mao, Xizeng
    Song, Xingzhi
    Zhang, Jianhua
    Pham, Lan, V
    Lorenzi, Philip L.
    Marszalek, Joseph
    Heffernan, Tim
    Draetta, Giulio
    Jones, Philip
    Futreal, Andrew
    Nomie, Krystle
    Wang, Linghua
    Wang, Michael
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (491)
  • [46] Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
    Molina-Arcas, Miriam
    Downward, Julian
    CANCER CELL, 2024, 42 (03) : 338 - 357
  • [47] Cellular Reprogramming as a Therapeutic Target in Cancer
    Xiong, Shumin
    Feng, Ye
    Cheng, Lin
    TRENDS IN CELL BIOLOGY, 2019, 29 (08) : 623 - 634
  • [48] G9a Responds to KRAS-Mediated Replication Stress by Increased Origin Licensing
    Thomas, Anju
    De Assuncao, Thiago Milech
    Lomberk, Gwen
    FASEB JOURNAL, 2022, 36
  • [49] METABOLIC REPROGRAMMING AND SUBSEQUENT AUTOPHAGY TRIGGERED BY KRAS GENE MUTATION IS A NOVEL PREVENTIVE TARGET AGAINST PANCREATIC CARCINOGENESIS
    Suzuki, Tatsunori
    Otsuka, Motoyuki
    Kishikawa, Takahiro
    Ohno, Motoko
    Sekiba, Kazuma
    Ishibashi, Rei
    Yamagami, Mari
    Seimiya, Takahiro
    Tanaka, Eri
    Koike, Kazuhiko
    GASTROENTEROLOGY, 2019, 156 (06) : S762 - S762
  • [50] Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
    Zhu, Liang
    Ji, Juntao
    Ma, Jianjia
    Wang, Dan
    Liu, Muyun
    Du, James Xianxing
    Chen, Rong
    Hou, Wei
    Abbruzzese, James L.
    Logsdon, Craig D.
    Yang, Vincent W.
    Luo, Yongde
    Lu, Weiqin
    CANCERS, 2022, 14 (11)
12345